Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Naltrexone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Inventage Lab Introduces ‘One-Month Long-Acting’ Drug Addiction Injection on the International Stage
Details : IVL3004 (naltrexone) is an opiod antagonist. It is a one-month long-acting injection based on company's IVL-DrugFluidic® technology. It is designed to treat opioid addiction.
Product Name : IVL3004
Product Type : Controlled Substance
Upfront Cash : Inapplicable
June 10, 2023
Lead Product(s) : Naltrexone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Leuprolide Acetate
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Daewoong Pharmaceutical
Deal Size : Undisclosed
Deal Type : Collaboration
Daewoong Partners with Inventage to Expand Long-Acting Injection Biz
Details : Both companies collaborate to discover a long-acting injection pipeline, research dosage form, conduct pre-clinical and clinical studies, and build overseas partnerships.
Product Name : Luphere
Product Type : Peptide
Upfront Cash : Undisclosed
May 25, 2020
Lead Product(s) : Leuprolide Acetate
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Daewoong Pharmaceutical
Deal Size : Undisclosed
Deal Type : Collaboration